Amarillo Biosciences Announces Two Additional Clinical Sites for Phase 2 Study of Orally Administered Interferon Alpha in the Treatment of Oral Warts in HIV-Positive Patients

AMARILLO, TX--(MARKET WIRE)--Jun 21, 2007 -- Amarillo Biosciences, Inc. (ABI) (OTC BB:AMAR.OB - News) today announced that by the end of June, two new clinical sites -- in Newark, New Jersey and Philadelphia, Pennsylvania -- will be ready to enroll patients in a Phase 2 study to test low-dose interferon alpha lozenges administered orally to HIV-positive subjects with oral warts. The Company's goal is to add five more clinical sites in the next 90 days to ensure the timely enrollment and completion of the study.